Enter your details to join our mobile app waitlist and receive early access to the Bell Direct App.
In this episode of From the Helm, John Konstantopoulos, CEO & Co-Founder of Artrya Limited (ASX:AYA), joins us to discuss the company’s AI-powered approach to transforming cardiac diagnostics and improving patient outcomes.
John provides an overview of Artrya’s strategy and commercial progress, explaining how its software platform leverages artificial intelligence to assist clinicians in detecting coronary artery disease earlier and more accurately. He also highlights the differentiation of Artrya’s Salix product suite, recent milestones, and what lies ahead as the company scales globally.
In this interview, John covers:
• introduction to Artrya, its strategy and commercial progress
• how the platform works and uses AI to support better cardiac outcomes
• key differentiators of the Salix product portfolio
• what investors can expect over the next 12 months
• the SAPPHIRE study, participating US hospital groups and intended outcomes
• the size of the addressable market opportunity
• key catalysts behind the company’s recent market cap growth
Note: This interview was filmed on 25 March 2026.